Impact of glucocorticoid therapy on hypothalamic-pituitary-adrenal axis function in pediatric nephrotic syndrome: A narrative review
Authors:
Open Access
- 9 December 2025
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Pediatrics
- Vol. 14 (4) , 110374
Abstract
Glucocorticoids (GCs) such as prednisolone are widely used in conditions like nephrotic syndrome, asthma, and autoimmune diseases. However, prolonged or high-dose use may suppress the hypothalamic-pituitary-adrenal (HPA) axis, leading to secondary adrenal insufficiency (AI). This condition occurs when the adrenal glands fail to produce adequate cortisol, which is essential for regulating metabolism, immune response, and stress adaptation. Corticotropin-releasing hormone (CRH) from the hypothalamus stimulates the pituitary to release adrenocorticotropic hormone (ACTH), which then triggers cortisol production in the adrenal glands. Prolonged GC use disrupts this system by inhibiting CRH and ACTH secretion, leading to adrenal atrophy and reduced cortisol production. HPA axis suppression is primarily diagnosed through dynamic tests. Early morning cortisol levels above > 18 ng/mL typically indicate normal function, while levels < 3 ng/mL suggest AI. Intermediate values require additional testing, such as the insulin tolerance test, ACTH stimulation test, and metyrapone test. Prednisolone in nephrotic syndrome suppresses the HPA axis, heightening AI risk, influenced by dose, duration, and timing of administration. Careful GC management is essential to balance disease control with risks of HPA axis suppression. Early recognition and timely intervention can prevent adrenal crises and improve outcomes in pediatric patients.Keywords
This publication has 46 references indexed in Scilit:
- Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old DrugsNew England Journal of Medicine, 2005
- Monitoring adverse reaction to steroid therapy in children.2004
- Increased Maintenance Corticosteroids during Upper Respiratory Infection Decrease the Risk of Relapse in Nephrotic SyndromeNephron, 2000
- Is the Prevalence of Addison’s Disease Underestimated?The Journal of Clinical Endocrinology & Metabolism, 1999
- The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases.The Journal of Clinical Endocrinology & Metabolism, 1995
- Risk of relapse in steroid-sensitive nephrotic syndrome: Effect of stage of post-prednisone adrenocortical suppressionThe Journal of Pediatrics, 1983
- Corticosteroids and hypothalamic-pituitary-adrenocortical function.BMJ, 1980
- GLUCOCORTICOID THERAPYMedicine, 1976
- Drug Spotlight ProgramAnnals of Internal Medicine, 1974
- RECOVERY OF HYPOTHALAMO-PITUITARY-ADRENAL FUNCTION AFTER CORTICOSTEROID THERAPYThe Lancet, 1967